Member Info for Scarabbeatle

As RM said early on, Data, data, data. With the hospital trials they were able to collect as many samples as possible. Blood, sputem etc. There is alot of information out there to do with interferons, this will be the first gold standard UK trial with interferon b 1a against covid 19. If the results are similar to other trials, and have some basis on previous sars mers data, then this has the potential to be the first treatment for covid 19, as an early intervention against the fatal progressive covid 19. Pandemic.

The trial, said no statistical difference between the 3 groups, all three of the groups had interferon alpha, with the different arms for different combination of the other drugs. 20 patients got withdrawn from the study of 101, due to adverse effects from lop/rit. No patients died.

Proportion of Patients With Illness Progression
We also assessed proportion of patients with illness progression among the three groups by comparing different proportion of patients re-classified as severe cases, and mortality rate during the study period. We found that one patient (3.0%) in the RBV+IFN-a-treated group, two patients (5.6%) in the LPV/r+IFN-a-treated group, and two patients (6.3%) in the RBV+LPV/r+IFN-a-treated group had been re-classified as severe cases of COVID-19. However, no statistically significant difference was observed among the three groups, and between any two of the three groups. Gratifyingly, there was no mortality in our cohort of 101 patients during the study period (Table 2).

Let them do the research and trial, then swoop in just after the results. :o.

This rns shows the demand for a product such as affirmers, this demand will not go away, even when this current c19 dies down, testing waste water is here to stay.

With shortages of reagents worldwide, avct is a stand alone diamond, with extra companies after the affirmers, defo no need to panic. Very strong here.

Already globally recognised

A bit more info from skin. I will have a break for a minute. But my understanding is real time monitoring which can identify a virus in waste water within seconds and transmit that info via a platform to registrar the presence of the virus.
Wed, 26th Feb 2020 07:00

RNS Number : 1136E
Integumen PLC
26 February 2020

AIM share code: SKIN

26 February 2020



Integumen PLC



("Integumen" or "Company")



Launch of ecowaterOS for real-time water monitoring, recovery, treatment and recycling



Fin Murray promoted to COO, Paul Ryan to CSO



Expansion of sales and science team



Integumen announces the launch of ecowaterOS ("Ecological Water Operating System"), a green-tech data management eco-system that monitors and analyses water for bacteria contamination using artificial intelligence. ecowaterOS will provide a broad range of clients from water utilities to consumers with alerts as to the contamination of water supplies in real-time and the provision of services from a consortium of water decontamination solution providers.



ecowaterOS initial consortium members include:



· Rinocloud AI

· Acumen Software

· Nimbus Research Centre

· Cork Institute of Technology

· Cellulac plc

· Modern Water plc

· tcBB Resource Centre



Promotions and new hires:

Fionan (Fin) Murray, current director and Group Sales Director, becomes Chief Operations Officer, effective immediately and Paul Ryan is promoted to Chief Sales Officer across all divisions of Integumen as the demand for Integumen's services and subsequent growth requires further expansion of sales and scientific teams to cover multi-national clients on four continents.



Gerard Brandon CEO Integumen plc, Cellulac plc and ecowaterOS member commented:

"The consortium brings together multiple partners with a combined 32 years of tried and tested engineering skillsets added to smart AI cloud-based data analytic technologies and best-in-class engineering at commercial scale across the brewing, biofuel, chemical and wastewater industries. With raising awareness of the direct impact of climate change across the world on systems vital to our wellbeing, ecowaterOS is a global game-changer for water monitoring, recovery, treatment and recycling."



Simon Humphrey, CEO of Modern Water commented:

"We are delighted to be able to provide the knowledge and expertise of our water monitoring services and supplies along with decontamination systems to the ecowaterOS multi-continental consortium. This unique platform of integrated water management systems, from contamination detection to decontamination is a world first end-to-end hi-tech solution to community, regional and continental-wide water shortages."

New partners much more than waste water. Rare regents not a problem for avct who make their own. Much more to skin than waste water. Massive step for affirmer tech on a completely different platform.

This from Skin
Wed, 3rd Jun 2020 07:00

RNS Number : 7393O
Integumen PLC
03 June 2020

AIM share code: SKIN



Integumen PLC



("Integumen" or "Company")



Labskin partners with University of Aberdeen to test COVID19 anti-viral skin and dental products



Integumen today announces that its subsidiary, Labskin, will begin the immediate testing of anti-viral treatments on Labskin cloned human skin coated with SARS-CoV-2 virus to investigate the use of consumer and dental care products that have the potential to mitigate the risk of transmission of the disease.



Labskin has secured access to the SARS-CoV-2 virus Category 3 laboratory at the University of Aberdeen to assess the strain "SARS-CoV-2 England/2/2020" regarding its transmissibility impact to and from human skin without exposing human volunteers to dangerous clinical trial contamination risk:



· Study the transferability of viral particles from materials to skin

· Assess the ability of the virus to remain infective while on the skin surface

· Quantify the efficacy of mouthwash and dental care products

· Quantify the efficacy of soap washing and hand sanitisers





Gerard Brandon - CEO of Integumen plc, comments:

"COVID-19 has had such a dramatic impact on lives across world, it is important to find products that can help to mitigate the risk of infection, particularly, in professional settings. Labskin is in a unique position to aid the fight against COVID-19 and with the support of the University of Aberdeen, can facilitate testing of the COVID-19 virus on our cloned human skin. We will study the effects of a variety of products and ingredients in the university's secure Containment Level 3 laboratory environment without exposing human volunteers to dangerous and challenging clinical trial contamination risk. The more knowledge we have about SARS-CoV-2 - how it spreads, and more importantly, how to contain that spread - the better equipped to fight this virus we will be."



Skin, transmissibility and infection control trial

The trial involves testing anti-viral treatments on cloned human skin coated with SARS-CoV-2 enabling Labskin to investigate the use of washes and sanitizers and their effectiveness. It will determine:



1. If the virus is transmissible from different surfaces to airways via skin by measuring its viability when recovered from surface(s) to skin.

2. Sanitizers efficiency to kill the virus on skin.

3. The reduction of titer and/or virulence.

Results of the trial are expected in the next six weeks.



Dental practice infection risk

The trial will also investigate consumer and pre-procedural mouthwash dental care products that may mitigate the risk of transmission in dental practices using Labskin grown to mimic the oral and nasal cavities. Given the widespread transmission of SARS-CoV-2, and reports of its spread to health care providers, den

Wed, 20th May 2020 10:32

RNS Number : 4858N
Modern Water PLC
20 May 2020



AIM share code: MWG

20 May 2020



Modern Water PLC



("Modern Water" or "Company")



Modern Water Microtox LX declared winner in China laboratory instrument award



Modern Water's newest laboratory biotoxicity analyser, Microtox LX[i], has been announced the Winner of the "Scientific Instrument Excellent New Product" award by the Chinese first scientific instrument professional portal (Instrument.com.cn). The winner was announced in a virtual ceremony of the Instrument Information Network.



The "Scientific Instrument Excellent New Product" selection event is held once a year. Microtox LX was originally shortlisted to 344 instruments in August 2019 by a panel of experts, from more than 9,000 new instruments out of nearly 1,500 companies.



Simon Humphrey CEO of Modern Water commented:

"Following two years of development and launching in 2019, we are delighted to have received such auspicious recognition with this top award in China for our latest Microtox range of laboratory equipment. Having a sales and support team in Shanghai, China is important and builds on more than 30 years of the Microtox water contamination testing brand. This award highlights the importance of water contamination, especially during the COVID-19 global health crisis.

Have a look at some recent rns from both mwg and skin, agree much smaller mcap and 1-2p for the last few months. But for testing purposes the virus can be identified up to a week before in waste water in local areas allowing for areas to be locked down.

Well I didn't see that coming, I have been following and am invested in both mwg and skin. Mwg have won a new product development award in China out of 1500 entries for their water products. This with skin, and now avct all ties up to be another arm to this company, good start to the day

T. L. The affirmer bind to the virus, stopping it from binding to anything else. Therefore Neutralising it.

I think in one of AS presentation he talks about low cost, mass bulk and quick turn around of affirmers, compared to antibodies.

Most definalty, but with some people showing no signs of symptoms, and some people having mild symptoms, if sng001 can give a little boost to people before the need to go to hospital then that in it self maybe a major benefit to the NHS in this country and also around the world.

Travel_light was talking about the pd1 inhibitors, that is somthing I had previously overlooked, if Avcata can trial and prove that, then that would be the new standard of medication, potentially without the need for chemo, as it will enable the bodies own defenses to attack the tumour cells as would be identified as an invader and dealt with by the immune response.

Yes agree with the ace 2 receptor. The virus getting into the system is through the mouth, nose, lungs, eyes. Inhaled interferon should hopefully deal with 3 out of the 4. And boost the immune system. So much more to understand about this virus.

Fantastic article and highlights the benefits of interferon beta, I would imagine the IV route solely in hospital treatment. With a higher dose possibly having more side effects? A targeted dose direct to the lungs potentially more beneficially? Or Nolupus if the dose isn't enough for the other benefits?

This is somthing I overlooked. A fantastic arm of research makes this company even more desirable

My apologies TL, I have misunderstood, I fully agree with what you have said.